AZD 5213
Alternative Names: AZD5213Latest Information Update: 05 Nov 2023
At a glance
- Originator AstraZeneca
- Class Analgesics; Nootropics; Small molecules
- Mechanism of Action Histamine H3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Attention-deficit hyperactivity disorder; Diabetic neuropathies; Gilles de la Tourette's syndrome; Mild cognitive impairment
Most Recent Events
- 01 May 2015 AstraZeneca completes a phase II trial for painful Diabetic neuropathies in USA (NCT01928381)
- 01 Feb 2015 AstraZeneca completes a phase II trial in Tourette's syndrome (in adolescents) in USA (NCT01904773)
- 01 Nov 2013 Phase-II clinical trials in Diabetic neuropathies in USA (PO)